WIXLIB

BRIAN FORTUNESenior Managing Diretor, Farragut SquareGroupAs Farragut’s President and Political Strategist, Brian leads FSG’sWashington team and is responsible for the firm’s research and diligencework. Before co-founding Farragut, Brian was the Political Strategistand a Managing Director of Marwood. Previously, he served theRepublican leadership in the U.S. House of Representatives for a decade,working primarily for former Speaker John Boehner (R-OH) andMajority Leader Dick Armey (R-TX).While representing the House leadership, Brian served as Staff Directorof Legislative Digest, the policy analysis and communications divisionof the House Republican Conference. In that role, he worked with thesenior staff on all House committees, concentrating primarily on issuesbefore the Ways and Means, Energy and Commerce, and AppropriationsCommittees. During this period, Brian worked directly with leadershipon all of the major healthcare initiatives, including BBA97, BBRA,HIPAA and BIPA 2000. He is a graduate of Oregon State University.ANNA FRENCHPrincipal, Qiming Venture PartnersAnna French, PhD joined Qiming Venture Partners USA in 2017 and isbased in Cambridge, MA. Prior to joining the Qiming team, Anna was amanagement consultant at the Boston Consulting Group (BCG) whereshe advised leading biopharma companies on their strategy andoperations. She also led a global industry-academic consortium focusedon cell therapy.

JENNIFER GEETTERPartner, McDermott Will & EmeryWith a practice focused primarily on the development, delivery andimplementation of digital health solutions, data and research, Jennifer S.Geetter works closely with both adopters and developers to bring theirinnovative healthcare solutions to patients and providers. In order todesign and deploy digital health technologies effectively, Jenn offersvaluable guidance on key issues, like patient on-boarding, providerimplementation, privacy and regulatory issues. She advises global lifesciences, healthcare and informatics clients on legal issues attendant todigital health, biomedical innovation, research compliance, globalprivacy and data security laws, and financial relationship management.DAVID HAIGHManaging Director and Co-Founder, AtlanticGlobal RiskDavid is a Managing Director and Co-Founder of Atlantic. David isresponsible for management of deal execution and implementingAtlantic’s growth initiatives. David and his team work with leadingfinancial sponsors and strategic clients across a variety of sectors,supporting transactions between 5m and 18bn in enterprise value.David is a thought leader in the M&A insurance space and speaksregularly at industry events about market trends and best practices.Prior to joining Atlantic, David was head of North Americantransactions for a leading European M&A insurance broker. In hisprevious role, David supported financial sponsors and corporates oninbound, outbound and intra-North American transactions. David startedhis career in the Energy Sector, working as a project engineer for Oil &Gas and Defense projects.

MARSHALL JACKSON, JRPartner, McDermott Will & EmeryMarshall E. Jackson, Jr. focuses his practice on transactional andregulatory counseling for clients in the healthcare industry, as well asadvises clients on the legal, regulatory and compliance aspects of digitalhealth. Marshall advises healthcare providers, private equity firms andtheir portfolio companies, and technology companies involved in “digitalhealth” – the intersection of health software applications, analyticaltools, medical technology and electronic data assets enabled by theInternet and mobile devices –on a variety of legal, regulatory andcompliance matters with a particular focus on digital health topics,including telehealth, telemedicine, mobile health and consumer wellness.Such engagements include assisting clients in developing andimplementing telehealth programs by advising on issues related toprofessional licensure, scope of practice, informed consent, prescribingand reimbursement.LAURA JEHLGlobal Head of Privacy and CybersecurityPractice, McDermott Will & EmeryLaura Jehl serves as global head of the Firm’s Privacy and CybersecurityPractice. Focusing on the intersection of data, law and emergingtechnologies, Laura advises clients on a broad range of privacy andcybersecurity issues. She has extensive experience identifying andmitigating privacy and data protection issues arising out of thecollection, use and storage of data as well as the design of new businessmodels, products and technologies. With unique experience as a formersenior in-house counsel and C-suite executive, she understands thebusiness, legal and technological challenges and opportunities her clientsface and helps develop innovative approaches to maximize the value oftheir data-based assets.

BYRON KALOGEROUPartner, McDermott Will & EmeryByron S. Kalogerou is the founder of the Firm’s Life Science IndustryGroup and is the senior partner in the Boston Corporate Practice. Hefocuses his practice on domestic and cross-border mergers andacquisitions, finance, and joint ventures and alliances. He has substantialon-the-ground experience structuring mergers, acquisitions, divestituresand joint ventures on six continents. Byron has extensive industrybackground in the life science, industrial and manufacturing sectors. Healso acts as outside general counsel to a number of companies.DEBBIE LINExecutive Director, Boehringer IngelheimVenture FundDr. Debbie Lin is Executive Director at Boehringer Ingelheim VentureFund in the US and leads the Fund’s North American efforts in DigitalHealthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008.Within Boehringer Ingelheim Pharma, she worked across variousregions and divisions. She has worked in Medical Affairs in the area ofwomen’s health and later in Health Economics and Outcomes supportingall commercial product sales with large payers and providers accountson the West Coast. She also led the US organization’s socialentrepreneurship program in Boehringer Ingelheim’s Making MoreHealth collaboration with Ashoka.In 2013, she transitioned to Corporate Headquarters in Germany inCorporate Strategy and Development as Director of CorporateDevelopment. There she was responsible for BI’s global developmentstrategy, leading BI’s global venture into stroke rehabilitation. She ledmulti-country teams to set up the company’s first stroke rehabilitationcenters in Shanghai, China and in Lisbon, Portugal. Prior to BoehringerIngelheim, she worked as a Public Policy Consultant for Pacific HealthPolicy Group supporting Medicaid Policy implementation in variousstates such as Vermont and West Virginia during the ClintonAdministration. Her doctorate is in Pharmacogenomics andBioinformatics from UCSF, she also has a Masters in Engineering fromStanford University and a Masters in Public Policy from UCLA.

JOANNA LINPartner, McDermott Will & EmeryJoanna Jung-Erh Lin focuses her practice on corporate, securities andtransactional matters. Along with many types of transactions, shehandles domestic and cross-border venture financing, mergers andacquisitions for public and private companies, and complex transitionservices agreements. She also has experience with capital marketstransactions, having represented US and international issuers, investmentbanks and investors in a wide range of securities offerings, includinginitial public offerings (IPOs), follow-on offerings and privateplacements of equity securities. Joanna also regularly counsels clients onmatters ranging from corporate governance to US Securities andExchange Commission periodic reporting requirements and othergeneral corporate matters.BRIAN MALKINPartner, McDermott Will & EmeryBrian Malkin counsels pharmaceutical and biologic clients on Food andDrug Administration (FDA) regulatory matters and intellectual property(IP) law, with an emphasis on patent litigation. His practice at theintersection of FDA- regulated products and patent law makes him avaluable partner to drug manufacturers, biotechnology clients, medicaldevice companies and cannabis companies as they develop new productsand protect their innovations though life cycle management, bring theirproducts to market and pursue transactional opportunities.

PATRICE MCNICOLLCo-Head of Investment Banking, B. RileySecurities, Inc.Patrice McNicoll is currently the Co-Head of Investment Banking at B.Riley Securities, Inc. Prior to joining B. Riley, Mr. McNicoll created andserved as Chief Executive Officer of MLV & Co., a boutique investmentbank which he sold to FBR in 2015. Mr. McNicoll was a managingdirector at Cantor Fitzgerald & Co, in New York where he played a keyrole in originating revenues and building the firm's investment bankingpractice. Mr. McNicoll structured and executed various capital markettransactions for small and large Real Estate Investment Trusts andcompanies in the energy, technology, biotechnology, and shippingsectors. Mr. McNicoll received a Bachelor of Arts with Honors inEconomics from York University, in Toronto, Canada and a Master ofBusiness Administration with a concentration in finance from McGillUniversity, Montreal, Canada.MARIAN NAKADAVice President, Venture Investments,Johnson & Johnson InnovationMarian Nakada, VP Venture Investments for Johnson & JohnsonInnovation – JJDC, has almost 30 years of experience in thepharmaceutical industry, starting her career at the laboratory bench atCentocor and moving to a research leadership role before Centocor’sacquisition by Johnson & Johnson in 1999. She transitioned to JanssenBusiness Development where she executed deals to support theexpansion of the Biologics portfolio. She joined JJDC, Johnson &Johnson’s corporate venture group in 2013. She is passionate aboutleveraging Johnson & Johnson’s capabilities to help her portfoliocompanies succeed. Marian has a B.A. in Biology from HarvardCollege and a Ph.D. in Pharmacology from the University ofPennsylvania. She is currently on the Boards of NavitorPharmaceuticals, Twenty-eight Seven Therapeutics, Ribon Therapeuticsas well as the New England Venture Capital Association where she isworking to champion change as an active contributor to its Diversity &Inclusion Committee.

NATHAN PELZERFounder and CEO, Clinify HealthNathan Pelzer is the Founder and CEO of Clinify Health, a digital healthcompany that works with physician practices located in underservedcommunities to achieve financial stability and remain independent.Prior to founding Clinify, Nathan was the Head of Corporate Strategyfor VillageMD a national primary care provider organization located inChicago where he was responsible for coordinating strategic initiativesto improve patient health outcomes while reducing overall cost of care.Prior to this role Nathan spent his career in senior level positions withinthe advisory services firms working across various aspects of thehealthcare industry. Nathan has a B.S. in Finance from The Universityof Minnesota and an M.B.A. from the University of Chicago – BoothSchool of Business.ROB PEREZOperating Partner, General Atlantic;Founder, Life Science CaresRob Perez is an Operating Partner and part of General Atlantic’sOperations Group, providing strategic support and advice to the firm’sinvestment team and portfolio companies in the Life Sciences sector.Before joining General Atlantic in 2019, he was Managing Director ofVineyard Sound Advisors, LLC, an advisory practice focused on growthcompanies in the biopharma industry. Prior to that, Rob was Presidentand CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in2015. Before joining Cubist in 2003, he served as Vice President ofBiogen, Inc.’s CNS Business Unit.

VERNESSA POLLARDChair, FDA Practice, McDermott Will &EmeryVernessa Pollard works alongside life sciences, medical device andtechnology companies, helping them navigate US Food and DrugAdministation (FDA) regulatory complexities to bring noveltechnologies and cutting-edge products to market. As a trusted advisorand legal strategist for multi-national life science companies, start-upsand investors, she helps clients develop practical, scalable andinnovative strategies for solving challenging regulatory and complianceproblems, evaluating risk and achieving business objectives.RENE QUASHIEVice President, Policy and Regulatory Affairs,Digital Health, Consumer TechnologyAssociationRené Quashie is the first-ever Vice President of Policy & RegulatoryAffairs of Digital Health at the Consumer Technology Association.Quashie provides guidance on key technical and regulatory issuesrelating to consumer digital health and wellness technology products,services, software and apps. Quashie will also work on behalf of CTA’sHealth and Fitness Technology Division , which supports the consumerhealth technology industry through education, research, standards work,policy initiatives and more. The division’s industry-consensusaccomplishments include the creation of CTA’s Guiding Principles onthe Privacy and Security of Personal Wellness Data , addressing howcompanies should treat consumers’ personal wellness data. CTA worksclosely with the Food and Drug Administration, the Centers forMedicare and Medicaid Services, the Office of the National Coordinatorand other related government agencies. Quashie previously was inprivate law practice at several national firms, and earned his law degreefrom George Washington University.

VIVEK RAMASWAMYFounder and CEO, Roivant SciencesVivek Ramaswamy is Founder and Chief Executive Officer of RoivantSciences. Roivant advances the development and delivery of importantmedicines in disease areas where the magnitude of R&D investmentfrom industry is disproportionately low relative to societal needs.Roivant also builds technology-focused subsidiaries focused onimproving the process of developing and commercializing medicines.Roivant and its family of companies employ over 900 professionalstoday.Mr. Ramaswamy graduated summa cum laude in Biology from HarvardUniversity in 2007 and began his career as a successful biotech investorwhere he oversaw investment in numerous companies, including thosethat helped develop curative treatment regimens for hepatitis C virus. Hecontinued to work as an investor while earning his law degree from YaleLaw School, where he was a Paul & Daisy Soros Fellow.MICHAEL RYANPartner, McDermott, Will & EmeryWith deep experience in the life sciences industry, Michael W. Ryanadvises manufacturers, healthcare providers, drug and technologydevelopers, and investors on the legal, regulatory and reimbursementissues that arise during the development and commercialization ofmedical devices, clinical laboratory testing services, biological productsand drugs. He guides life sciences companies and laboratories byevaluating and implementing strategies to optimize coding, coverage andpayment for novel technologies. Michael also helps innovativecompanies identify and navigate applicable FDA regulatoryrequirements for new technologies, particularly in vitro diagnostics anddigital health products. In particular, he regularly advises clients on theFDA’s evolving requirements for laboratory developed tests (LDTs) anddigital health products, such as clinical decision support (CDS) software.

FREDERIC SCAEROULead Director, Business Development &Licensing, Oncology, ServierPharmaceuticalsMICHAEL SIEKMANPartner, McDermott Will & EmeryMichael Siekman focuses his practice on intellectual property matters,including patent prosecution, licensing and post-grant proceedings andlitigation. Leveraging over 25 years of experience, Michael has built indepth patent portfolios, advising clients in the biotechnology andpharmaceutical industries.Michael keeps clients’ business goals in mind as he regularly provideslegal counsel in the litigation matters, including Hatch-Waxman matters,and post-grant solutions for biosimilars. He has successfully led mattersbefore the Patent Trial and Appeal Board (PTAB) and the EuropeanPatent Office. His licensing practice involves IP-related aspects ofmergers, acquisitions, IPOs and other financing and licensing programs.RICHARD SMITHCounsel, McDermott Will & EmeryRichard B. Smith focuses his practice on representation of life sciencescompanies and related transactions. He has served as counsel to public,private and emerging life sciences companies, advising those companieson strategic business transactions such as licensing, joint ventures, andcollaborations involving research, development, marketing, supply,clinical development and co-promotion of pharmaceutical, diagnosticand medical device products.Richard also advises companies on other corporate issues common tolife sciences companies, including corporate formation of new ventures,venture capital, private equity, and venture philanthropy.

EMMANUELLE TROMBEPartner, McDermott Will & EmeryEmmanuelle Trombe represents pharmaceutical, medical device and biopharmaceutical companies globally in transactional matters in relation toM&A and divestitures, joint ventures and strategic partnerings, largescale projects, outsourcing projects, product development, licensingagreements and regulatory matters. She also advises venture capitalfunds and bio-pharmaceutical companies in connection with a broadrange of financing activities.Emmanuelle Trombe is distinguished in Chambers Europe and Legal500 EMEA in life sciences transactions, where she is recommended forher expertise in the pharmaceutical, health care, biotech and medicaldevices industries and described as very responsive, smart, flexible andbusiness-minded.KWAME ULMERVenture Partner, Wavemaker Three-SixtyHealth; Founder, MedTech ColorKwame Ulmer is a venture partner at Wavemaker Three-Sixty Health the leading Southern-California based, early stage venture capital firm(Seed and Series A) focused on the healthcare industry. He participatesin all aspects of fund management (e.g. deal sourcing, diligence,negotiation and advising portfolio company management teams).Kwame brings nearly twenty years of experience evaluating medicaltechnologies in the government and private sector, and serving in senioroperating roles at medical device companies. He has personallyevaluated more than 1,000 medical technologies in his career. Kwamespent 12 years at the U.S. Food and Drug Administration (FDA) inprogressive leadership roles, including Deputy Director and BranchChief. He also served as Vice President, Regulatory Affairs and QualityAssurance at Implant Direct, a Danaher Corporation operating company.He is a member of the Executive Committee of Tech Coast Angels (LA),the world’s largest angel investing network and serves on the steeringcommittee of ScaleLA, the leading healthcare innovation space in LosAngeles. Kwame earned his B.S. in Physics from Lincoln University,and has two Masters degrees from the University of Virginia, inMaterials Engineering and Business Administration.

SUSAN VAN METERExecutive Director, AdvaMedDxSusan Van Meter is executive director of AdvaMedDx. AdvaMedDxrepresents manufacturers of in vitro diagnostic (IVD) tests andtechnologies. AdvaMedDx member company innovat

technology companies on a broad range of corporate and securities matters. She was also seconded to Sumitomo Chemical Co. Ltd.'s legal department in Tokyo, where she managed an array of in-house legal issues. Prior to that she was corporate counsel at Marvell Technology, Inc. Chiu is a graduate of the University of Virginia School of Law. She .